BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27100877)

  • 21. Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ.
    Adamo HH; Halin Bergström S; Bergh A
    PLoS One; 2015; 10(6):e0130076. PubMed ID: 26076453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel non-canonical Wnt signature for prostate cancer aggressiveness.
    Sandsmark E; Hansen AF; Selnæs KM; Bertilsson H; Bofin AM; Wright AJ; Viset T; Richardsen E; Drabløs F; Bathen TF; Tessem MB; Rye MB
    Oncotarget; 2017 Feb; 8(6):9572-9586. PubMed ID: 28030815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression patterns of potential therapeutic targets in prostate cancer.
    Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
    Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer.
    Zedan AH; Hansen TF; Assenholt J; Pleckaitis M; Madsen JS; Osther PJS
    Tumour Biol; 2018 May; 40(5):1010428318775864. PubMed ID: 29775158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatial modeling of prostate cancer metabolic gene expression reveals extensive heterogeneity and selective vulnerabilities.
    Wang Y; Ma S; Ruzzo WL
    Sci Rep; 2020 Feb; 10(1):3490. PubMed ID: 32103057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
    Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer.
    Hansen AF; Sandsmark E; Rye MB; Wright AJ; Bertilsson H; Richardsen E; Viset T; Bofin AM; Angelsen A; Selnæs KM; Bathen TF; Tessem MB
    Oncotarget; 2016 Jul; 7(27):42071-42085. PubMed ID: 27276682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.
    Grzmil M; Thelen P; Hemmerlein B; Schweyer S; Voigt S; Mury D; Burfeind P
    Am J Pathol; 2003 Aug; 163(2):543-52. PubMed ID: 12875974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of metabolite concentrations in benign and malignant prostate tissues using 3D proton MR spectroscopic imaging.
    Weis J; von Below C; Tolf A; Ortiz-Nieto F; Wassberg C; Häggman M; Ladjevardi S; Ahlström H
    J Magn Reson Imaging; 2017 Apr; 45(4):1232-1240. PubMed ID: 27556571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer.
    Weng J; Wang J; Hu X; Wang F; Ittmann M; Liu M
    Int J Cancer; 2006 Mar; 118(6):1471-80. PubMed ID: 16206286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells.
    Weber A; Klocker H; Oberacher H; Gnaiger E; Neuwirt H; Sampson N; Eder IE
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30037119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
    Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues.
    Singh KK; Desouki MM; Franklin RB; Costello LC
    Mol Cancer; 2006 Apr; 5():14. PubMed ID: 16595004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.
    Simak R; Capodieci P; Cohen DW; Fair WR; Scher H; Melamed J; Drobnjak M; Heston WD; Stix U; Steiner G; Cordon-Cardo C
    Histol Histopathol; 2000 Apr; 15(2):365-74. PubMed ID: 10809354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring candidate biomarkers for lung and prostate cancers using gene expression and flux variability analysis.
    Asgari Y; Khosravi P; Zabihinpour Z; Habibi M
    Integr Biol (Camb); 2018 Feb; 10(2):113-120. PubMed ID: 29349465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.
    Zha S; Ferdinandusse S; Hicks JL; Denis S; Dunn TA; Wanders RJ; Luo J; De Marzo AM; Isaacs WB
    Prostate; 2005 Jun; 63(4):316-23. PubMed ID: 15599942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
    Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
    Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.